Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6806127 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (SAD) | EXPERIMENTAL | Adaptive model per protocol |
| Part 2: Food Effect (FE) | EXPERIMENTAL | Fasted versus Fed |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo, administered orally with approximately 240 mL of buffer |
| RO6806127 | DRUG | Administered orally with approximately 240 mL of buffer |
Inclusion Criteria: * Healthy male participants aged 18 to 45 years, inclusive * A BMI between 18 to 30 kg/m2, inclusive * Agreement to use highly effective contraception Exclusion Criteria: * Clinically significant abnormalities in laboratory test results * History of any clinically significant ...
RO6806127 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy male volunteers. The specific disease indications for which it is being developed have not been disclosed, and it remains in early clinical development.
RO6806127 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the Phase 1 study evaluating the compound in healthy male volunteers.
RO6806127 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
RO6806127 has been evaluated in one Phase 1 trial, NCT02196636, titled A Phase 1 Study of RO6806127 in Healthy Male Volunteers. The trial was completed, enrolled 37 participants, was randomized, double blind, and controlled, and was conducted in the United States.
RO6806127 is an investigational agent that has been studied in healthy male volunteers rather than in patients with a specific disease. Its intended therapeutic indications have not been disclosed, so no approved or established use exists for the compound.